CoChat
Sign Up
Cited by 31

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Hepatic decompensation during direct-acting antiviral therapy of chronic hepatitis C

Hoofnagle, Jay H.·2016·Journal of Hepatology
DOI 10.1016/j.jhep.2016.01.007
Open this paper in CoChat — free account

Overview

Integrity signals

Registry

Crossref · 10.1016/j.jhep.2016.01.007

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In patients with Child-Pugh class B and decompensated cirrhosis (class C), the hepatotoxicity of protease inhibitors for hepatitis C and obeticholic acid for primary biliary cholangitis is significantly increased.

    “For example, in patients with Child-Pugh class B and decompensated cirrhosis (class C), the hepatotoxicity of protease inhibitors for hepatitis C and obeticholic acid for primary biliary cholangitis is significantly increased [107,108].”

    From Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update (2024) · cites this paper as [107]

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 17

  1. 2015, AASLD/IDSA Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing and treating adults infected with hepatitis C virus, Hepatology, 62, 932, 10.1002/hep.27950 · DOI
  2. Afdhal, 2014, Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection, N Engl J Med, 370, 1889, 10.1056/NEJMoa1402454 · DOI
  3. Feld, 2014, Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin, N Engl J Med, 370, 1594, 10.1056/NEJMoa1315722 · DOI
  4. Zeuzem, 2014, Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin, N Engl J Med, 370, 1604, 10.1056/NEJMoa1401561 · DOI
  5. Feld, 2015, Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection, N Engl J Med, 373, 2599, 10.1056/NEJMoa1512610 · DOI
  6. Foster, 2015, Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection, N Engl J Med, 373, 2608, 10.1056/NEJMoa1512612 · DOI
  7. Curry, 2015, Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis, N Engl J Med, 373, 2618, 10.1056/NEJMoa1512614 · DOI
  8. Charlton, 2015, SOLAR-1 Investigators. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease, Gastroenterology, 149, 649, 10.1053/j.gastro.2015.05.010 · DOI
  9. Saxena, 2015, Safety and efficacy of simeprevir/sofosbuvir in hepatitis C-infected patients with compensated and decompensated cirrhosis, Hepatology, 62, 715, 10.1002/hep.27922 · DOI
  10. Welker, 2016, Lactic acidosis in patients with hepatitis C virus related cirrhosis and combined ribavirin/sofosbuvir treatment, J Hepatol, 64, 790, 10.1016/j.jhep.2015.11.034 · DOI
  11. Funk, 2007, Acid-base disturbances in critically ill patients with cirrhosis, Liver Int, 27, 901, 10.1111/j.1478-3231.2007.01510.x · DOI
  12. Coats, 2014, Chutes and ladders in hepatitis C nucleoside drug development, Antiviral Res, 102, 119, 10.1016/j.antiviral.2013.11.008 · DOI
  13. Xu, 2014, Fialuridine induces acute liver failure in chimeric TK-NOG mice: a model for detecting hepatic drug toxicity prior to human testing, PLoS Med, 11, 31001628, 10.1371/journal.pmed.1001628 · DOI
  14. Hézode, 2014, CUPIC Study Group. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis, Gastroenterology, 147, 132, 10.1053/j.gastro.2014.03.051 · DOI
  15. Kalafeteli, 2015, Clinical decompensation after achieving SVR with sofosbuvir, daclatasvir and ribavirin in a patient with recurrent HCV post-liver transplant, J Gastrointestin Liver Dis, 24, 257
  16. Stine, 2014, Hepatic decompensation likely attributable to simeprevir in patients with advanced cirrhosis, Dig Dis Sci, 60, 1031, 10.1007/s10620-014-3422-x · DOI
  17. Dyson, 2016, Liver toxicity associated with sofosbuvir, an NS5A inhibitor and ribavirin use, J Hepatol, 64, 234, 10.1016/j.jhep.2015.07.041 · DOI

Cited by

Sorted by citations

Metadata

Authors
Hoofnagle, J. H.
Venue
Journal of Hepatology
Publisher
Elsevier BV
Published
2016-04
Volume
64
Issue
4
Pages
763-765
ISSN
0168-8278
DOI
10.1016/j.jhep.2016.01.007
Cited by
31
References
1
Language
en
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review